<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79016">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02023346</url>
  </required_header>
  <id_info>
    <org_study_id>13-253</org_study_id>
    <nct_id>NCT02023346</nct_id>
  </id_info>
  <brief_title>Prognostic Awareness and Patient-Physician Communication in Malignant Glioma</brief_title>
  <official_title>Prognostic Awareness and Patient-Physician Communication in Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about patients with brain tumors understanding of
      their disease and their communication with their physician. Ultimately, we hope to use these
      findings to improve communication between patients and their doctors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>measure prognostic awareness</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>Malignant Glioma patients</arm_group_label>
    <description>This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, except Dr. Eli Diamond's patients and respective caregivers, will be screened for eligibility and willingness to participate in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>surveys and cognitive tests</intervention_name>
    <arm_group_label>Malignant Glioma patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from the inpatient Neurology service.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient Inclusion Criteria

          -  Age greater than or equal to 18

          -  Diagnosis of any WHO grade III or IV glioma

          -  Admitted to the inpatient Neurology service

          -  Has had at least one outpatient visit with a neuro-oncologist at MSKCC Fluent in
             English

        Caregiver Inclusion Criteria

          -  Age greater than or equal to 18

          -  Identified by the patient as a relative, friend, or partner with whom he or she has a
             significant relationship and who provides him or her physical or emotional
             assistance.

          -  The patient has himself or herself agreed to participate in this study

        Exclusion Criteria:

        Patient Exclusion Criteria

          -  A patient will be excluded if the Glasgow Coma Scale is less than 15, with one
             exception: if the score is 14 because of disorientation to date only, as evaluated in
             the verbal assessment, the patient is eligible to participate. The patient must be
             oriented to self, age, place, and year, and month.

          -  Aphasia precluding comprehension and verbalization of consent to participate

          -  Is a patient of Dr. Eli Diamond

          -  Patients who cannot verbally demonstrate their understanding of the risks, benefits,
             and alternatives to participating in the study. This evaluation will take place for
             otherwise eligible and willing participants, and it will be performed by the NP or MD
             clinician who is obtaining informed consent and will be documented in the medical
             record.

        Caregiver Exclusion Criteria

          -  No eligible caregivers who can complete the brief assessment in person will be
             excluded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Diamond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eli Diamond, MD</last_name>
    <phone>212-639-7576</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa DeAngelis, MD</last_name>
    <phone>212-639-7123</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>New Yori</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Diamond, MD</last_name>
      <phone>212-639-7576</phone>
    </contact>
    <contact_backup>
      <last_name>Lisa DeAngelis, MD</last_name>
      <phone>212-639-7123</phone>
    </contact_backup>
    <investigator>
      <last_name>Eli Diamond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>December 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient-Physician Communication</keyword>
  <keyword>Brain cancer</keyword>
  <keyword>13-253</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
